DB-1303/BNT323
Phase 3Small molecule
DB-1303/BNT323 is one of 31 small molecule programs targeting HER2-positive Advanced Solid Tumor. It is currently in Phase 3.
2
Indications
3
Total Trials
3
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1DB-1303/BNT323
DDualityBio Inc.
Phase 3
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DB-1303/BNT323. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- DDualityBio Inc.